Top Markets
Coin of the day
GeneOne Life Science, Inc. GeneOne Life Science, Inc.

GeneOne Life Science, Inc.

011000
株式のランク #27557
GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul,... GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.
株価
$1.85
最終同期: 2026-07-27
時価総額
$32.07M
変化(1日)
0.00%
変化(1年)
-76.96%
KR
取引 GeneOne Life Science, Inc. (011000)

カテゴリー

GeneOne Life Science, Inc.(011000)の株価履歴
終値の最高値: $1.85 (2026-07-01)

終値の最安値: $23.84 (2001-06-01)
GeneOne Life Science, Inc. の株価履歴(2001 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -22.96%
2025 -4.07%
2024 -33.27%
2023 -63.32%
2022 -63.83%
2021 13.31%
2020 1,037.04%
2019 -41.12%
2018 -28.27%
2017 -35.06%
2016 1.77%
2015 22.45%
2014 42.10%
2013 -12.14%
2012 10.82%
2011 -5.48%
2010 -21.62%
2009 76.56%
2008 -76.28%
2007 -40.52%
2006 -4.38%
2005 344.79%
2004 -0.52%
2003 -33.37%
2002 7.03%
2001 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$120.74 -14.98%
AU
$760.31 6.82%
CH